- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02518451
Bioequivalence Evaluation of Two Film-Coated Formulations of Valsartan 160 mg
Bioequivalence Study of 160 mg Valsartan Film-coated Caplets Produced by PT Dexa Medica in Comparison With the Innovator Film-coated Tablets (Diovan® 160, Novartis Pharma AG)
Study Overview
Status
Conditions
Detailed Description
In the first period, subjects received either the test formulation (160 mg valsartan film-coated caplets produced by PT Dexa Medica, Palembang, Indonesia) once daily, or the innovator film-coated tablets (Diovan® 160, Novartis Farmaceutica S.A., Barbera del Valles, Spain for Novartis Pharma AG, Basel, Switzerland) once daily as the reference formulation. In the subsequent period, after a one-week wash-out period, they received the alternate drug.
At the night before starting the study, subjects were instructed to fast from any food and drink but mineral water for 9 hours before the drug administration. In the morning after, at the dosing day, each of the 48 subjects then swallowed (without chewing) one dose of valsartan 160 mg of the test formulation or of the reference formulation, with 200 mL of water. As much as 5 mL of blood samples for drug assay were drawn again from each subject, at 0.5, 1, 1.5, 2, 2.5, 3, 3.5, 4, 6, 9, 12, 16, 24, 36, and 48 hours after dosing.
The concentrations of valsartan in plasma were assayed using a validated high performance liquid chromatography with fluorescence detector (HPLC-FL) method. Pharmacokinetic parameters, including the area under the concentration-versus-time curve (AUC) from time zero to the time of last quatifiable concentration (48 hours after dosing) (AUC-t), AUC from time zero extrapolated to infinity (AUC-inf), maximum concentration (Cmax), time to reach the maximum concentration (tmax), and half-life (t1/2), were assessed in this study.
Study Type
Enrollment (Actual)
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
-
Jakarta, Indonesia, 12430
- PT Equilab International
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Male and female subjects with absence of significant disease or clinically significant abnormal laboratory values on laboratory evaluation, medical history or physical examination during screening.
- Aged 18 - 55 years inclusive
- Preferably non-smokers or smoke less than 10 cigarettes per day.
- Able to participate, communicate well with the investigators and willing to provide written informed consent to participate in the study.
- Body mass index within 18 to 25 kg/m2.
Vital signs (after 10 minutes rest) must be within the following ranges:
- Systolic blood pressure : 110 - 120 mm Hg
- Diastolic blood pressure : 70 - 80 mm Hg
- Pulse rate : 60 - 90 bpm
Exclusion Criteria:
- Personal/family history of allergy or hypersensitivity or contraindication to valsartan or allied drugs.
- Pregnant or lactating women (urinary pregnancy test will be applied to women subjects just before taking the study drug).
- Any major illness in the past 90 days or clinically significant ongoing chronic medical illness e.g. congestive heart failure, hepatitis, hypotensive episodes, hyperglycemia, etc.
- Presence of any clinically significant abnormal values during screening e.g. significant abnormality of liver function test (ALT, alkaline phosphatase, total bilirubin >= 1.5 ULN), renal function test (serum creatinine concentration > 1.4 mg/dL), etc.
- Positive Hepatitis B surface antigen (HBsAg), anti-HCV, or anti-HIV.
- Clinically significant haematology abnormalities.
- Clinically significant electrocardiogram (ECG) abnormalities.
- Any surgical or medical condition (present or history) which might significantly alter the absorption, distribution, metabolism or excretion of the study drug, e.g. gastrointestinal diseases including gastric or duodenal ulcers or history of gastric surgery.
- Past history of anaphylaxis or angioedema.
- History of drug or alcohol abuse within 12 months prior to screening for this study.
- Participation in any clinical trial within the past 90 days calculated from the last visit.
- History of any bleeding or coagulative disorders.
- History of difficulty with donating blood or difficulty in accessibility of veins in left or right arm.
- A donation or loss of 300 mL (or more) of blood within 3 months before this study's first dosing day.
- Intake of any prescription or non-prescription drug, food supplement or herbal medicine within 14 days of this study's first dosing day.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: TREATMENT
- Allocation: RANDOMIZED
- Interventional Model: CROSSOVER
- Masking: SINGLE
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
EXPERIMENTAL: (Test) Group I
Valsartan 160 mg film-coated caplets of PT Dexa Medica
|
In each of the two study periods (separated by a washout of one week) a single dose of test or reference formulation was administered.
Other Names:
|
ACTIVE_COMPARATOR: (Reference) Group II
Valsartan 160 mg film-coated caplets (Diovan® 160)
|
In each of the two study periods (separated by a washout of one week) a single dose of test or reference formulation was administered.
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
AUCt
Time Frame: 48 hours
|
Area under the curve of plasma concentrations versus time from time zero to the time of last observed quantifiable concentration was determined from plasma concentration of two valsartan160 mg film-coated caplets formulations (test and reference formulations)
|
48 hours
|
AUCinf
Time Frame: 48 hours
|
Area under the curve of plasma concentrations versus time from time zero to infinity was determined from plasma concentration of two valsartan160 mg film-coated caplets formulations (test and reference formulations)
|
48 hours
|
Cmax
Time Frame: 48 hours
|
The maximum (peak) plasma concentration was determined from plasma concentration of two valsartan160 mg film-coated caplets formulations (test and reference formulations)
|
48 hours
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Tmax
Time Frame: 48 hours
|
The time of peak plasma concentration was determined from plasma concentration of two valsartan160 mg film-coated caplets formulations (test and reference formulations)
|
48 hours
|
T1/2
Time Frame: 48 hours
|
The elimination half-life was determined from plasma concentration of two valsartan160 mg film-coated caplets formulations (test and reference formulations)
|
48 hours
|
Other Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Adverse events
Time Frame: 1 months
|
The presence of adverse events will be observed, reported and sufficiently handled during subjects' participation in the study (1 month).
|
1 months
|
Collaborators and Investigators
Sponsor
Investigators
- Study Director: Effi Setiawati, MSc, PT. Equilab International
Study record dates
Study Major Dates
Study Start
Primary Completion (ACTUAL)
Study Completion (ACTUAL)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (ESTIMATE)
Study Record Updates
Last Update Posted (ESTIMATE)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- PR. 183/EQL/2010
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Healthy
-
Prevent Age Resort "Pervaya Liniya"RecruitingHealthy Aging | Healthy Diet | Healthy LifestyleRussian Federation
-
Maastricht University Medical CenterCompletedHealthy Volunteers | Healthy Subjects | Healthy AdultsNetherlands
-
Yale UniversityNot yet recruitingHealth-related Benefits of Introducing Table Olives Into the Diet of Young Adults: Olives For HealthHealthy Diet | Healthy Lifestyle | Healthy Nutrition | CholesterolUnited States
-
Hasselt UniversityRecruitingHealthy | Healthy AgingBelgium
-
Galera Therapeutics, Inc.Syneos HealthCompleted
-
Galera Therapeutics, Inc.Syneos HealthCompletedHealthy | Healthy VolunteersAustralia
-
University of PennsylvaniaActive, not recruitingHealthy | Healthy AgingUnited States
-
Chalmers University of TechnologyGöteborg UniversityCompletedHealthy | Nutrition, HealthySweden
-
University of ManitobaNot yet recruitingHealthy | Healthy Diet
-
King's College LondonUniversity of ReadingCompletedHealthy | Healthy AgingUnited Kingdom
Clinical Trials on Valsartan 160 mg film-coated caplets (test formulation)
-
Future University in EgyptCompleted
-
BayerCompleted
-
Qanatpharma Canada LTDCompletedHealthy VolunteerCanada
-
H. Lundbeck A/SCompletedBioequivalence Study in Healthy SubjectsRussian Federation
-
Max Zeller Soehne AGCompleted
-
Future University in EgyptCompletedHealthy SubjectsEgypt
-
Pharmtechnology LLCClinPharmInvest, LLCNot yet recruitingBioequivalenceRussian Federation
-
Pharmtechnology LLCClinPharmInvest, LLCCompletedBioequivalenceRussian Federation
-
Pharmtechnology LLCClinPharmInvest, LLCUnknownBioequivalenceRussian Federation
-
University of Alabama at BirminghamNational Heart, Lung, and Blood Institute (NHLBI)RecruitingCardiovascular Diseases | Diabetes Mellitus | Insulin Sensitivity/Resistance | Metabolic Disease | Energy Expenditure | Metabolism | Natriuretic PeptidesUnited States